The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 05, 2022

Filed:

Dec. 30, 2017
Applicant:

Aiviva Biopharma, Inc., Las Vegas, NV (US);

Inventors:

Diane Dan-shya Tang-Liu, Las Veas, NV (US);

Tiffany Constance Liu, Las Vegas, NV (US);

Gerald Woodrow Devries, San Clemente, CA (US);

Assignee:

AIVIVA BIOPHARMA, INC., Las Vegas, NV (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/47 (2006.01); A61K 9/00 (2006.01); A61K 31/5025 (2006.01); A61K 31/404 (2006.01); A61K 31/44 (2006.01); A61K 31/496 (2006.01); A61K 31/506 (2006.01);
U.S. Cl.
CPC ...
A61K 31/5025 (2013.01); A61K 31/404 (2013.01); A61K 31/44 (2013.01); A61K 31/47 (2013.01); A61K 31/496 (2013.01); A61K 31/506 (2013.01); A61K 9/0019 (2013.01); A61K 9/0031 (2013.01);
Abstract

A method for preventing, treating and/or improving a prostatic disease or disorder associated with epithelial hyperplasia and/or fibrosis, comprising: administering an effective amount of a multikinase inhibitor to a subject in need thereof, wherein the multikinase inhibitor has a certain spectrum of kinase inhibitory activity. The multikinase inhibitor is sunitinib, regorafenib, ponatinib, pazopanib, nintedanib and/or lenvatinib. The prostatic disease or disorder is selected from the group consisting of benign prostate hyperplasia and its associated lower urinary tract symptoms, fibrosis of ureters and renal pelvis, prostate adenoma, and prostatic intraepithelial neoplasia in animals and humans.


Find Patent Forward Citations

Loading…